ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1855

Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

Gary Macfarlane1, Roxanne Cooksey2, Ernest Choy3 and Rosemary Hollick4, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Cardiff University, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 4University of Aberdeen, Aberdeen, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Comorbidity, fibromyalgia, Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1840–1861) Health Services Research Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how best to design services to deliver effective care. Much of the available evidence characterising the health and use of health services for people with fibromyalgia comes from small studies or in highly-selected groups. The use of routinely collected health data offers the possibility of large and unselected samples to better quantify the characteristics of people with fibromyalgia and their use of health services.

Methods: A case-control study of patients with fibromyalgia using deidentified National Health Service health and care data held in the Secured Anonymised Information Linkage (SAIL) databank for the whole population of Wales. Individuals ≥18 years and with a code present for fibromyalgia in their primary care records between 2004-18 formed the case group. Each case was matched with up to four controls: by sex, age; socio-economic status and with a code for any health care use within 30 days of the code date of the case. We analysed past events in their primary care record for cases and controls.

Results: 19,742 cases and 76,746 controls were included in this analysis. The vast majority of cases were female (89%) and had a median age of 48 years. The mean BMI was higher in cases (30.3 v. 28.8 kgm-2) who were also more likely to have smoked (73 v. 68%), and have comorbidities (with the exception of cancer) (Table 1), specifically Inflammatory Arthritis (5.4 v. 2.2%) and Inflammatory Bowel Disease (1.9 v. 1.1%) . Depression/anxiety was recorded in 74% of cases, while sleep disorders were also common (24.8%). The use of anti-depressants was near universal in people with fibromyalgia (95%), opiates prescription common (82%), while gabapentin was used by 51% and steroids by 44%. Codes for tress and bereavement (27.2 v. 17.6%) and specifically adverse life events (10.7% v. 8.8%) were significantly more common in cases. In the year prior to diagnosis referrals to 17 out of the 20 specialties examined were more common in cases – particularly for Gastroenterology, Neurology, Pain Management, General Surgery and Orthopaedics (Table 2). Only 1 in 20 of cases have been referred to Rheumatology prior to the first recording of fibromyalgia in their records, however almost half had been referred to each of General Surgery, Orthopaedics and Gynaecology.

Conclusion: This whole population approach has quantified the burden of comorbidities in people diagnosed with fibromyalgia, and highlighted the very common use of opiates whose use is recommended against. The previously reported role of adversity in the aetiology of the condition is replicated. This large unselected-sample approach offers potential for understanding interactions with healthcare of people before and after diagnosis of fibromyalgia (and relating to these to patient characteristics); investigating the opportunities for harm; and the design of more efficient and effective approaches to their care.

Supporting image 1

Table 1: Prevalence of comorbidities in cases (fibromyalgia) and controls

Supporting image 2

Table 2: Referral to specialist outpatient one year pre-fibromyalgia diagnosis (cases) and index date (controls)


Disclosures: G. Macfarlane: None; R. Cooksey: None; E. Choy: AbbVie, 2, 6, Amgen, 2, 6, Bio-Cancer, 5, Biogen, 2, 5, Chugai Pharma, 2, 6, Eli Lilly, 2, 6, Fresenius Kabi, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Janssen, 2, Novartis, 5, Pfizer, 5, 6, R-Pharm, 2, Sanofi, 2, 5, 6, Sanofi-Genzyme, 2, UCB, 2; R. Hollick: CSL Vifor, 6.

To cite this abstract in AMA style:

Macfarlane G, Cooksey R, Choy E, Hollick R. Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/using-a-whole-population-approach-to-help-design-more-effective-and-efficient-healthcare-services-for-people-with-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-a-whole-population-approach-to-help-design-more-effective-and-efficient-healthcare-services-for-people-with-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology